Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

Rhea-AI Summary

Exicure (Nasdaq: XCUR) will present a poster at the 2026 Tandem Meetings (ASTCT/CIBMTR) in Salt Lake City on February 5, 2026, summarizing results from its open-label, multicenter Phase 2 trial (NCT05561751) of burixafor for hematopoietic progenitor cell mobilization in multiple myeloma patients undergoing autologous hematopoietic cell transplantation.

The company reported positive topline data showing 89.7% of patients met the trial primary endpoint; burixafor was given with propranolol and G-CSF and enabled same-day administration and leukapheresis with a reported favorable safety profile.

Positive

• Primary endpoint met: 89.7% of patients achieved target mobilization
• Same-day collection: burixafor enabled same-day administration and leukapheresis
• Combination regimen: burixafor + propranolol + G-CSF provided reliable mobilization

Negative

• Phase 2, open-label: data are from a non‑pivotal, open‑label study
• Encore presentation: poster is an encore of previously reported topline data (no new readout date provided)

Argus Jan 21 session

+2.28% close to close Open Argus

Details

News Market Reaction – XCUR

On Jan 21, the day this news came out, XCUR closed 2.28% above the previous close.

Data tracked by StockTitan Argus for the Jan 21 session.

Key Figures

Primary endpoint success: 89.7% of patients Trial phase: Phase 2 Abstract number: 29283 +2 more

Primary endpoint success

89.7% of patients

Phase 2 burixafor trial in multiple myeloma (AHCT setting)

Trial phase

Phase 2

Open-label, multicenter burixafor study (NCT05561751)

Abstract number

29283

Tandem Meetings poster presentation identifier

Meeting dates

February 4–7, 2026

2026 Tandem Meetings in Salt Lake City, UT

Presentation time

February 5, 2026, 6:30 PM

Poster session on graft sources and mobilization

Historical Context

5 past events · Latest: Dec 08

5 events

1. Dec 08

   Phase 2 topline data

   24h Move

   +8.8%

   Positive Phase 2 burixafor topline data and safety profile in myeloma.

2. Nov 07

   Q3 2025 earnings

   24h Move

   -2.3%

   Cash decline to $4.4M and need for substantial near-term financing.

3. Nov 03

   ASH oral presentation

   24h Move

   -4.3%

   Announcement of completed Phase 2 data oral presentation at ASH.

4. Oct 06

   Program update

   24h Move

   +2.4%

   Phase 2 primary endpoint met and plans for broader burixafor development.

5. Aug 08

   Q2 2025 earnings

   24h Move

   +1.7%

   Cash drop to $7.9M and urgent need for additional financing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

autologous hematopoietic cell transplantation, CXCR4, chemokine receptor, hematopoietic stem cells, +4 more

8 terms

autologous hematopoietic cell transplantation medical

"patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (AHCT)."

A procedure that collects and stores a patient’s own blood-forming stem cells, delivers high-dose chemotherapy or radiation to clear diseased bone marrow, then returns those stored cells to rebuild the blood and immune system. Think of it like removing an engine, doing major repairs to a car, and reinstalling the original engine so it fits perfectly and lowers the chance of rejection. Investors watch this because its use, success rates, cost, and related technologies affect hospital demand, drug development, and long-term treatment economics.

CXCR4 medical

"by blocking CXCR4, a chemokine receptor that plays a central role in retaining"

CXCR4 is a protein on the surface of many cells that acts like a lock for a specific chemical signal, guiding cells where to go and how to behave. It matters to investors because drugs that block or mimic this receptor can change immune responses, stop cancer cells from spreading, help mobilize stem cells for transplants, or affect viral entry; thus CXCR4-targeted therapies can drive clinical value, regulatory milestones, and licensing or partnership opportunities.

chemokine receptor medical

"by blocking CXCR4, a chemokine receptor that plays a central role in retaining"

A chemokine receptor is a protein on the surface of immune cells that detects and responds to small signaling molecules called chemokines, guiding cells to sites of inflammation, infection, or injury. For investors, these receptors matter because they are common drug targets and biomarkers: medicines that block or activate them can change disease outcomes, regulatory approval can create commercial value, and progress in related trials often affects company valuation much like a successful GPS upgrade can make a delivery service far more efficient.

hematopoietic stem cells medical

"plays a central role in retaining hematopoietic stem cells in the bone marrow niche."

Hematopoietic stem cells are the body’s blood-forming “seed” cells that sit in bone marrow and continually produce red blood cells, white blood cells and platelets. They matter to investors because therapies or tests that use or affect these cells can treat cancers, immune disorders and blood diseases; successful clinical results or approvals can create large markets and change a company’s value like a new product line transforming a factory’s revenue.

bone marrow niche medical

"hematopoietic stem cells in the bone marrow niche. Blockade of this pathway"

The bone marrow niche is the local environment inside bone marrow that supports blood-forming stem cells, supplying signals, nutrients and structural support that control how those stem cells grow, divide or stay dormant. Investors care because therapies or drugs that change this niche can alter blood and immune cell production, affect outcomes of cancer or transplant treatments, and create commercial opportunities or risks tied to efficacy, safety and market adoption.

leukapheresis medical

"same-day administration and leukapheresis. This offers an important alternative"

Leukapheresis is a medical procedure that separates and removes white blood cells from a person’s blood, like running blood through a specialized filter to pull out a specific ingredient. It matters to investors because those collected cells are often the raw material for advanced therapies and clinical trials, so the availability, cost, production speed, and regulation of leukapheresis can directly affect a biotech company’s ability to manufacture treatments and generate revenue.

hematopoietic progenitor cells medical

"ability to mobilize hematopoietic progenitor cells by blocking CXCR4, a chemokine"

Hematopoietic progenitor cells are immature blood-forming cells that act like young saplings able to grow into different types of blood cells (red cells, white cells, platelets) but with less long-term self-renewal than true stem cells. For investors, they matter because they are the active agents in many blood-related therapies, transplants and drug tests—so their availability, safety and behavior directly affect treatment success, manufacturing and regulatory outcomes.

G-CSF medical

"burixafor in combination with propranolol and G-CSF provided reliable mobilization"

G‑CSF (granulocyte colony-stimulating factor) is a manufactured protein that prompts the bone marrow to produce neutrophils, a type of white blood cell that protects patients from infection after chemotherapy, bone marrow transplant, or severe illness. For investors, G‑CSF products matter because they fulfill a steady, clinical need—like safety gear hospitals must replenish—so changes in approvals, patents, manufacturing capacity, or competing biosimilars can meaningfully affect sales and company valuations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a poster at the upcoming 2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), taking place February 4-7, 2026, in Salt Lake City, UT.

The presentation will serve as an encore of data reported previously, highlighting results from Exicure’s open-label, multicenter Phase 2 trial (NCT05561751) evaluating burixafor in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (AHCT). Exicure recently shared positive topline data from the trial, which assessed burixafor’s ability to mobilize hematopoietic progenitor cells by blocking CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. Blockade of this pathway facilitates stem cell movement from the bone marrow into the peripheral blood for collection and use in transplantation procedures.

“Effective stem cell mobilization remains a challenge for patients with multiple myeloma undergoing autologous transplantation, particularly in the modern treatment era where exposure to lenalidomide- and daratumumab-based induction is common and mobilization options are limited,” said Yosra Aljawai, M.D., a lead investigator, poster presenter and Assistant Professor, Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center. “In our Phase 2 study, burixafor in combination with propranolol and G-CSF provided reliable mobilization and a favorable safety profile. 89.7% of the patients successfully met the primary endpoint, with the added advantage of same-day administration and leukapheresis. This offers an important alternative collection strategy for patients who may face barriers to successful stem cell collection.”

Poster Presentation Details
Abstract Number: 29283
Title: An Open-Label, Multi-Center Phase 2 study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with G-CSF for the Mobilization of Hematopoietic Progenitor Cells in Patients with Multiple Myeloma
Presenter: Dr. Yosra Aljawai, Assistant Professor, Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center
Session: Graft sources, mobilization, donor safety.
Date and Time: February 5, 2026, 6:30 PM

About Exicure
Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company’s lead program, burixafor (GPC-100), is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, burixafor may enhance stem cell mobilization into the peripheral blood to support collection and use in autologous hematopoietic cell transplantation (AHCT).

Burixafor is being evaluated for its potential to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. In addition, Exicure is planning a chemosensitization trial in acute myeloid leukemia (AML), leveraging burixafor’s ability to mobilize malignant cells from protective bone marrow niches into the peripheral blood, where they may be more effectively targeted by chemotherapy. Burixafor became part of Exicure’s pipeline following the company’s acquisition of GPCR Therapeutics, Inc. in January 2025. For more information, visit www.exicuretx.com.

Media Contact:
Sarah Ellinwood, PhD
Kendall Investor Relations
sellinwood@kendallir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Exicure (XCUR) present burixafor Phase 2 data at the 2026 Tandem Meetings?

The poster presentation is scheduled for February 5, 2026 at 6:30 PM during the Tandem Meetings in Salt Lake City.

What were the topline results for Exicure's (XCUR) burixafor Phase 2 trial?

Topline results reported that 89.7% of patients met the trial primary endpoint for hematopoietic progenitor cell mobilization.

What regimen was studied in Exicure's (XCUR) Phase 2 mobilization trial (NCT05561751)?

The study evaluated burixafor with propranolol and G-CSF for mobilization in multiple myeloma patients undergoing AHCT.

Does Exicure (XCUR) claim burixafor enables same-day stem cell collection?

Yes; the company reported burixafor allowed same-day administration and leukapheresis in the Phase 2 study.

What is the clinical status of burixafor for Exicure (XCUR)?

Burixafor is in a Phase 2 open-label trial assessing mobilization in multiple myeloma patients.

Where can investors find the Exicure (XCUR) poster details for the Tandem Meetings?

Poster details: Abstract 29283, title and presenter listed; session is 'Graft sources, mobilization, donor safety.'